Adenovirus infections and lung disease

Current Opinion in Pharmacology

Volumn 7, Issue 3, 2007, Pages 237-243

  Hayashi, Shizu ^a   Hogg, James C ^a  

^a The James Hogg iCAPTURE Centre for Cardiovascular and Pulmonary Research   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CIDOFOVIR; E1A PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 8; TRANSFORMING GROWTH FACTOR BETA1; VIRUS DNA; VIRUS VACCINE;

ADENOVIRUS; ARMY; BRONCHIOLITIS; BRONCHIOLITIS OBLITERANS; CHRONIC OBSTRUCTIVE LUNG DISEASE; DISEASE MODEL; DISEASE SEVERITY; EMPHYSEMA; EPITHELIUM CELL; HUMAN; IMMUNOCOMPROMISED PATIENT; INFLAMMATION; LUNG ALVEOLUS EPITHELIUM; LUNG DISEASE; NONHUMAN; PATHOGENESIS; PATHOPHYSIOLOGY; PEDIATRICS; PNEUMONIA; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; UPREGULATION; VIROLOGY; VIRUS INFECTION;

ADENOVIRIDAE INFECTIONS; ADENOVIRUS E1A PROTEINS; ANIMALS; HUMANS; IMMUNOCOMPROMISED HOST; LUNG DISEASES; MILITARY PERSONNEL;

EID: 34248572528     PISSN: 14714892     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.coph.2006.11.014     Document Type: Review

References (57)

1. Rowe W.P., Huebner R.J., Gilmore L.K., Parrott R.H., and Ward T.G. Isolation of a cytopathogenic agent from human adenoids undergoing spontaneous degeneration in tissue culture. Proc Soc Exp Biol Med 84 (1953) 570-573
2. Horowitz M.S. Adenoviruses. In: Knipe D.M., and Howley P.M. (Eds). Fields Virology. edn 4 (2001), Lippincott Williams & Wilkins 2310-2326
3. Hayashi S. Latent adenovirus infection in COPD. Chest 121 (2002) 183S-187S
4. Goncalves M.A., and de Vries A.A. Adenovirus: from foe to friend. Rev Med Virol 16 (2006) 167-186. Although this is mainly a review of adenovirus as a vector for gene therapy, the readers are directed to its introductory sections that provide a concise summary of the history, epidemiology, structure and life-cycle of the virus, details of which could not be presented in the current review on lung diseases. The review includes new findings on cellular receptors of the virus, endocystosis and viral packaging.
5. Horwitz M.S. Function of adenovirus E3 proteins and their interactions with immunoregulatory cell proteins. J Gene Med 6(Suppl 1) (2004) S172-S183
6. Schmitz H., Wigand R., and Heinrich W. Worldwide epidemiology of human adenovirus infections. Am J Epidemiol 117 (1983) 455-466
7. Marttila M., Persson D., Gustafsson D., Liszewski M.K., Atkinson J.P., Wadell G., and Arnberg N. CD46 is a cellular receptor for all species B adenoviruses except types 3 and 7. J Virol 79 (2005) 14429-14436
8. Shenk T.E. Adenoviridae: the viruses and their replication. In: Knipe D., and Howley P. (Eds). Fields Virology. edn 4 (2001), Lippincott Williams & Wilkins 2265-2300
9. Huebner R.J., Rowe W.P., Ward T.G., Parrott R.H., and Bell J.A. Adenoidal-pharyngeal-conjunctival agents: a newly recognized group of common viruses of the respiratory system. N Engl J Med 251 (1954) 1077-1086
10. Badger G.F., Curtiss C., Dingle J.H., Ginsberg H.S., Gold E., and Jordan Jr. W.S. A study of illness in a group of Cleveland families. X. The occurrence of adenovirus infections. Am J Hyg 64 (1956) 336-348
11. Brandt C.D., Kim H.W., Vargosko A.J., Jeffries B.C., Arrobio J.O., Rindge B., Parrott R.H., and Chanock R.M. Infections in 18,000 infants and children in a controlled study of respiratory tract disease. I. Adenovirus pathogenicity in relation to serologic type and illness syndrome. Am J Epidemiol 90 (1969) 484-500
12. Rosman F.C., Mistchenko A.S., Ladenheim H.S., do Nascimento J.P., Outani H.N., Madi K., and Lenzi H.L. Acute and chronic human adenovirus pneumonia: cellular and extracellular matrix components. Pediatr Pathol Lab Med 16 (1996) 521-541
13. Lang W.R., Howden C.W., Laws J., and Burton J.F. Bronchopneumonia with serious sequelae in children with evidence of adenovirus type 21 infection. BMJ 1 (1969) 73-79
14. Becroft D.M. Histopathology of adenovirus infection of the respiratory tract in young children. J Clin Pathol 20 (1967) 561-569
15. Hogg J.C., Irving W.L., Porter H., Evans M., Dunnill M.S., and Fleming K. In situ hybridization studies of adenoviral infections of the lung and their relationship to follicular bronchiectasis. Am Rev Respir Dis 139 (1989) 1531-1535
16. Pichler M.N., Reichenbach J., Schmidt H., Herrmann G., and Zielen S. Severe adenovirus bronchiolitis in children. Acta Paediatr 89 (2000) 1387-1389
17. Al-Shehri M.A., Sadeq A., and Quli K. Bronchiolitis in Abha, Southwest Saudi Arabia: viral etiology and predictors for hospital admission. West Afr J Med 24 (2005) 299-304
18. Colom A.J., Teper A.M., Vollmer W.M., and Diette G.B. Risk factors for the development of bronchiolitis obliterans in children with bronchiolitis. Thorax 61 (2006) 503-506. This report of the largest sample of pediatric patients with post-infectious bronchiolitis obliterans in the medical literature to date compares 109 bronchiolitis obliterans patients to 99 controls with bronchiolitis who subsequently did not develop bronchiolitis obliterans. Identification of adenovirus, respiratory syncitial virus, influenza and parainfluenza virus in nasopharyngeal secretions was made by indirect immunofluorescence viral tests. The risk factors assessed were gender, prenatal and postnatal environmental, tobacco smoke exposure, age < 6 months at the time of admission for bronchiolitits, specific viral aetiology for bronchiolitis, and the need for mechanical ventilation during admission. A multivariate logistic regression analysis of risk factors for bronchiolitis obliterans showed that the greatest risk factor was adenovirus infection, with an odds ratio of 49, followed by mechanical ventilation, with an odds ratio of 11.
19. Warner J.O., and Marshall W.C. Crippling lung disease after measles and adenovirus infection. Br J Dis Chest 70 (1976) 89-94
20. Kaschula R.O., Druker J., and Kipps A. Late morphologic consequences of measles: a lethal and debilitating lung disease among the poor. Rev Infect Dis 5 (1983) 395-404
21. Hilleman M.R., and Werner J.H. Recovery of new agent from patients with acute respiratory illness. Proc Soc Exp Biol Med 85 (1954) 183-188
22. Huebner R.J., Rowe W.P., and Chanock R.M. Newly recognized respiratory tract viruses. Annu Rev Microbiol 12 (1958) 49-76
23. Rosenbaum M.J., Edwards E.A., Frank P.F., Pierce W.E., Crawford Y.E., and Miller L.F. Epidemiology and prevention of acute respiratory disease in naval recruits. i. Ten years' experience with microbial agents isolated from naval recruits with acute respiratory disease. Am J Public Health Nations Health 55 (1965) 38-46
24. Mogabgab W.J. Acute respiratory illnesses in university (1962-1966) military and industrial (1962-1963) populations. Am Rev Respir Dis 98 (1968) 359-379
25. Gray G.C., Callahan J.D., Hawksworth A.W., Fisher C.A., and Gaydos J.C. Respiratory diseases among U.S. military personnel: countering emerging threats. Emerg Infect Dis 5 (1999) 379-385
26. Top Jr. F.H., Buescher E.L., Bancroft W.H., and Russell P.K. Immunization with live types 7 and 4 adenovirus vaccines. II. Antibody response and protective effect against acute respiratory disease due to adenovirus type 7. J Infect Dis 124 (1971) 155-160
27. Russell K.L., Broderick M.P., Franklin S.E., Blyn L.B., Freed N.E., Moradi E., Ecker D.J., Kammerer P.E., Osuna M.A., Kajon A.E., et al. Transmission dynamics and prospective environmental sampling of adenovirus in a military recruit setting. J Infect Dis 194 (2006) 877-885. A recent high-throughput technology was applied to identify serotypes of adenovirus in swab samples of the oropharynx and dominant hand from 271 military recruits, as well as from surfaces and the air of their environment, in the first four weeks of training. Triangulation-identification for the genetic evaluated risks (TIGER) uses broad PCR priming in combination with the determination of base composition of the amplicon by electrospray ionization and time-of-flight mass spectrometry to identify the pathogen. This is the first report of the application of this technology to serotype the virus. The study found that, although 79% were initially negative for antibodies to either adenovirus 4 or 7, the percentage of recruits positive for adenovirus 4 increased from 34% at enrolment to 97% by the end of the study. Furthermore, 87% of the 84 identified as having febrile respiratory illness were positive for adenovirus 4, and 14-50% of the 668 surface and air samples were positive.
28. Russell K.L., Hawksworth A.W., Ryan M.A., Strickler J., Irvine M., Hansen C.J., Gray G.C., and Gaydos J.C. Vaccine-preventable adenoviral respiratory illness in US military recruits. Vaccine 24 (2006) 2835-2842
29. Kojaoghlanian T., Flomenberg P., and Horwitz M.S. The impact of adenovirus infection on the immunocompromised host. Rev Med Virol 13 (2003) 155-171
30. Leen A.M., Bollard C.M., Myers G.D., and Rooney C.M. Adenoviral infections in hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 12 (2006) 243-251
31. Ison M.G. Adenovirus infections in transplant recipients. Clin Infect Dis 43 (2006) 331-339. Ison reviews the viral epidemiology in transplant recipients, showing that adenovirus disease in the stem cell transplantation population ranges from 3-47% (dependent upon the variables discussed in the current review). The authors report on the clinical presentation of adenoviral disease in this population, and the improvements seen following the application of quantitative real-time PCR in the diagnosis and monitoring of disease; they also describe studies to determine whether detection of virus by PCR in blood samples is effective as a screen to identify asymptomatic patients. In the management options section, an update on therapy options for the disease is given.
32. Pauwels R.A., Buist A.S., Ma P., Jenkins C.R., and Hurd S.S. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: national heart, lung, and blood institute and world health organization global initiative for chronic obstructive lung disease (gold): executive summary. Respir Care 46 (2001) 798-825
33. Hogg J.C., Macklem P.T., and Thurlbeck W.M. Site and nature of airway obstruction in chronic obstructive lung disease. N Engl J Med 278 (1968) 1355-1360
34. Van Brabandt H., Cauberghs M., Verbeken E., Moerman P., Lauweryns J.M., and Van de Woestijne K.P. Partitioning of pulmonary impedance in excised human and canine lungs. J Appl Physiol 55 (1983) 1733-1742
35. Yanai M., Sekizawa K., Ohrui T., Sasaki H., and Takishima T. Site of airway obstruction in pulmonary disease: direct measurement of intrabronchial pressure. J Appl Physiol 72 (1992) 1016-1023
36. Mead J., Turner J.M., Macklem P.T., and Little J.B. Significance of the relationship between lung recoil and maximum expiratory flow. J Appl Physiol 22 (1967) 95-108
37. Murray C.J., and Lopez A.D. Evidence-based health policy-lessons from the global burden of disease study. Science 274 (1996) 740-743
38. Gold D.R., Tager I.B., Weiss S.T., Tosteson T.D., and Speizer F.E. Acute lower respiratory illness in childhood as a predictor of lung function and chronic respiratory symptoms. Am Rev Respir Dis 140 (1989) 877-884
39. Matsuse T., Hayashi S., Kuwano K., Keunecke H., Jefferies W.A., and Hogg J.C. Latent adenoviral infection in the pathogenesis of chronic airways obstruction. Am Rev Respir Dis 146 (1992) 177-184
40. Elliott W.M., Hayashi S., and Hogg J.C. Immunodetection of adenoviral E1A proteins in human lung tissue. Am J Respir Cell Mol Biol 12 (1995) 642-648
41. Retamales I., Elliott W.M., Meshi B., Coxson H.O., Pare P.D., Sciurba F.C., Rogers R.M., Hayashi S., and Hogg J.C. Amplification of inflammation in emphysema and its association with latent adenoviral infection. Am J Respir Crit Care Med 164 (2001) 469-473
42. Vitalis T.Z., Keicho N., Itabashi S., Hayashi S., and Hogg J.C. A model of latent adenovirus 5 infection in the guinea pig (Cavia porcellus). Am J Respir Cell Mol Biol 14 (1996) 225-231
43. Vitalis T.Z., Kern I., Croome A., Behzad H., Hayashi S., and Hogg J.C. The effect of latent adenovirus 5 infection on cigarette smoke-induced lung inflammation. Eur Respir J 11 (1998) 664-669
44. Meshi B., Vitalis T.Z., Ionescu D., Elliott W.M., Liu C., Wang X.D., Hayashi S., and Hogg J.C. Emphysematous lung destruction by cigarette smoke. The effects of latent adenoviral infection on the lung inflammatory response. Am J Respir Cell Mol Biol 26 (2002) 52-57
45. Keicho N., Elliott W.M., Hogg J.C., and Hayashi S. Adenovirus E1A gene dysregulates ICAM-1 expression in transformed pulmonary epithelial cells. Am J Respir Cell Mol Biol 16 (1997) 23-30
46. Higashimoto Y., Elliott W.M., Behzad A.R., Sedgwick E.G., Takei T., Hogg J.C., and Hayashi S. Inflammatory mediator mRNA expression by adenovirus E1A-transfected bronchial epithelial cells. Am J Respir Crit Care Med 166 (2002) 200-207
47. Keicho N., Elliott W.M., Hogg J.C., and Hayashi S. Adenovirus E1A upregulates interleukin-8 expression induced by endotoxin in pulmonary epithelial cells. Am J Physiol 272 (1997) L1046-L1052
48. Keicho N., Higashimoto Y., Bondy G.P., Elliott W.M., Hogg J.C., and Hayashi S. Endotoxin-specific NF-kappaB activation in pulmonary epithelial cells harboring adenovirus E1A. Am J Physiol 277 (1999) L523-L532
49. Higashimoto Y., Keicho N., Elliott W.M., Hogg J.C., and Hayashi S. Effect of adenovirus E1A on ICAM-1 promoter activity in human alveolar and bronchial epithelial cells. Gene Expr 8 (1999) 287-297
50. Gilmour P.S., Rahman I., Hayashi S., Hogg J.C., Donaldson K., and MacNee W. Adenoviral E1A primes alveolar epithelial cells to PM(10)-induced transcription of interleukin-8. Am J Physiol Lung Cell Mol Physiol 281 (2001) L598-L606
51. Fujii T., Hogg J.C., Keicho N., Vincent R., Van Eeden S.F., and Hayashi S. Adenoviral E1A modulates inflammatory mediator expression by lung epithelial cells exposed to PM10. Am J Physiol Lung Cell Mol Physiol 284 (2003) L290-L297
52. Ogawa E., Elliott W.M., Hughes F., Eichholtz T.J., Hogg J.C., and Hayashi S. Latent adenoviral infection induces production of growth factors relevant to airway remodeling in COPD. Am J Physiol Lung Cell Mol Physiol 286 (2004) L189-L197
53. Hogg J.C., Chu F., Utokaparch S., Woods R., Elliott W.M., Buzatu L., Cherniack R.M., Rogers R.M., Sciurba F.C., Coxson H.O., et al. The nature of small-airway obstruction in chronic obstructive pulmonary disease. N Engl J Med 350 (2004) 2645-2653
54. Behzad A.R., Morimoto K., Gosselink J., Green J., Hogg J.C., and Hayashi S. Induction of intermediate phenotypes in lung epithelial cells by adenovirus E1A. Eur Respir J 28 (2006) 1106-1116. The results from this study demonstrate that adenovirus E1A induces epithelial to mesenchymal transformation in guinea-pig peripheral lung epithelial cells by reducing the expression of epithelial markers and by promoting mesenchymal phenotypes, including vimentin and smooth muscle α-actin expression. These changes might contribute to the remodeling process observed in the peripheral lung in COPD, in which latent adenovirus infection has been studied as a potential risk factor.
55. Yamada K., Elliott W.M., Hayashi S., Brattsand R., Roberts C., Vitalis T.Z., and Hogg J.C. Latent adenoviral infection modifies the steroid response in allergic lung inflammation. J Allergy Clin Immunol 106 (2000) 844-851
56. Yamada K., Elliott W.M., Brattsand R., Valeur A., Hogg J.C., and Hayashi S. Molecular mechanisms of decreased steroid responsiveness induced by latent adenoviral infection in allergic lung inflammation. J Allergy Clin Immunol 109 (2002) 35-42
57. Humar A., Doucette K., Kumar D., Pang X.L., Lien D., Jackson K., and Preiksaitis J. Assessment of adenovirus infection in adult lung transplant recipients using molecular surveillance. J Heart Lung Transplant 25 (2006) 1441-1446. This study shows that not all adenovirus infections in lung transplant patients are associated with the severe consequences reported previously. The authors attribute the source of this discrepancy to (i) the limitation of their patient population to adults rather than the more susceptible pediatric patients, (ii) the greater sensitivity of detection of virus by PCR, and (iii) detection of virus in the plasma as opposed to lung tissue, as well as other technical issues.